New eye injection aims to save sight in diabetes patients
NCT ID NCT05802329
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called OCU200, given as an injection into the eye, for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). The study will include 24 participants and will primarily check for safety and side effects, while also measuring vision changes. The goal is to see if OCU200 can help control the condition and preserve eyesight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCU200 (injected into the eye)
What this could lead to
If it works, this could point toward a new treatment to control vision loss from diabetic macular edema.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not improve vision or could cause side effects like eye pain or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Research LLC
RECRUITINGDeerfield Beach, Florida, 33064, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
Erie Retina Research, LLC
RECRUITINGErie, Pennsylvania, 16507, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gundersen Health System
RECRUITINGLa Crosse, Wisconsin, 54601, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Retina Consultants of America
RECRUITINGSouthlake, Texas, 76092, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Retina Consultants of Texas Research Centers
RECRUITINGBellaire, Texas, 77401, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••